In The Literature
Bone Marrow Transplant
Autologous stem cell transplant for multiple myeloma patients 70 years or older
J Clin Oncol
Association Between Treatment Facility Volume and Mortality of Patients With Multiple Myeloma
Biol Blood Marrow Transplant
Post-Transplant Outcomes in High-Risk Compared With Non-High-Risk Multiple Myeloma: A CIBMTR Analysis
Clin Lymphoma Myeloma Leuk
Clonal Evolution in Multiple Myeloma
Oncology (Williston Park)
COUNTERPOINT: Routine Use of Autologous Stem Cell Transplantation in Multiple Myeloma
Oncology (Williston Park)
POINT: Routine Use of Autologous Stem Cell Transplantation in Multiple Myeloma
Nat Rev Clin Oncol
Genomic complexity of multiple myeloma and its clinical implications
Hematol Oncol
Risk of stroke in patients with newly diagnosed multiple myeloma: a retrospective cohort study
J Manag Care Spec Pharm
Estimating the Economic Impact of Adding Panobinostat to a U.S. Formulary for Relapsed and/or Refractory Multiple Myeloma: A Budget Impact and Cost-Benefit Model
Biol Blood Marrow Transplant
Post-Transplant Outcomes in High-Risk Compared to Non-High Risk Multiple Myeloma
The Lancet Oncology
International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma.
Expert Review of Hematology
Real-World Treatment Patterns and Associated Progression-Free Survival in Relapsed/Refractory Multiple Myeloma Among US Community Oncology Practices
American Journal of Hematology
Multiple Myeloma: 2016 Update on Diagnosis, Risk Stratification, and Management
Journal of Clinical Oncology
Updated Outcomes and Impact of Age With Lenalidomide and Low-Dose Dexamethasone or Melphalan, Prednisone, and Thalidomide in the Randomized, Phase III FIRST Trial
Bone Marrow Transplant
Bendamustine, Etoposide and Dexamethasone to Mobilize Peripheral Blood Hematopoietic Stem Cells for Autologous Transplantation in Patients with Multiple Myeloma
Leukemia & Lymphoma
A Systematic Literature Review and Network Meta-Analysis of Treatments for Patients With Untreated Multiple Myeloma Not Eligible for Stem Cell Transplantation
The New England Journal of Medicine
Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
JNCCN—Journal of the National Comprehensive Cancer Network
NCCN Guidelines Insights: Multiple Myeloma
Current Opinion in Pharmacology
New Approaches to Targeting the Bone Marrow Microenvironment in Multiple Myeloma
European Journal of Haematology
Outcome of Allogeneic Transplantation in Newly Diagnosed and Relapsed/Refractory Multiple Myeloma: Long-Term Follow-Up in a Single Institution
Clinical Lymphoma, Myeloma & Leukemia
VANTAGE 095: An International, Multicenter, Open-Label Study of Vorinostat (MK-0683) in Combination With Bortezomib in Patients With Relapsed and Refractory Multiple Myeloma
Clinical Chemistry and Laboratory Medicine
Monitoring Multiple Myeloma Patients Treated With Daratumumab: Teasing Out Monoclonal Antibody Interference
Cancer Genomics & Proteomics
Identification of Prognostically Relevant Chromosomal Abnormalities in Routine Diagnostics of Multiple Myeloma Using Genomic Profiling
Leukemia & Lymphoma
Outcomes and Management of Lenalidomide-Associated Rash in Patients With Multiple Myeloma
American Journal of Hematology
Central Nervous System Involvement by Multiple Myeloma: A Multi-institutional Retrospective Study of 172 Patients in Daily Clinical Practice
Journal of Oncology Pharmacy Practice
Multiple Myeloma: Updates for Pharmacists in the Treatment of Relapsed and Refractory Disease
Leukemia & Lymphoma
Connect MM® – The Multiple Myeloma Disease Registry: Incidence of Second Primary Malignancies in Patients Treated With Lenalidomide
British Journal of Haematology
Chimeric Antigen Receptor (CAR) Therapy for Multiple Myeloma
Cellular and Molecular Life Sciences
Immune Responses in Multiple Myeloma: Role of the Natural Immune Surveillance and Potential of Immunotherapies
Bone Marrow Transplantation
Upfront plerixafor plus G-CSF versus cyclophosphamide plus G-CSF for stem cell mobilization in multiple myeloma: Efficacy and cost analysis study
Bone Marrow Transplantation
Allogeneic stem cell transplantation for multiple myeloma: Is there a future?
Leukemia and Lymphoma
Stem cell transplantation in multiple myeloma and other plasma cell disorders (report from an EBMT preceptorship meeting)
Blood Cancer Journal
Evaluating results from the multiple myeloma patient subset treated with denosumab or zoledronic acid in a randomized phase 3 trial
British Journal of Haematology
Efficacy and Safety of Salvage Therapy Using Carfilzomib for Relapsed or Refractory Multiple Myeloma Patients: A Multicentre Retrospective Observational Study
Journal of the National Cancer Institute
Maintenance Therapy With Immunomodulatory Drugs in Multiple Myeloma: A Meta-Analysis and Systematic Review
Acta Haematologica
The Shreveport Myeloma Experience: Survival, Risk Factors and Other Malignancies in the Age of Stem Cell Transplantation
Expert Review of Anticancer Therapy
Oral Ixazomib Maintenance Therapy in Multiple Myeloma
In The News
American Society of Hematology 2016 Annual Meeting
Session 731. Clinical Autologous Transplantation: Results: Clinical Autologous Transplantation in Myeloma I
American Society of Hematology 2016 Annual Meeting
Session 653. Myeloma: Therapy, excluding Transplantation: IMiD/Proteasome Inhibitor Combinations and Maintenance Therapy
American Society of Hematology 2016 Annual Meeting
Abstract 1143: Lenalidomide Is a Highly Effective Maintenance Therapy in Myeloma Patients of All Ages; Results of the Phase III Myeloma XI Study
American Society of Hematology 2016 Annual Meeting
Abstract 673: Intensification Therapy with Bortezomib-Melphalan-Prednisone Versus Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma: An Intergroup, Multicenter, Phase III Study of the European Myeloma Network (EMN02/HO95 MM Trial)
In The Literature
Bone Marrow Transplant